Utilizing Biomarkers to Navigate Treatment Decisions for Prostate Cancer Patients

Target Audience
The educational design of this activity addresses the needs of medical oncologists, radiation oncologists, urologists, nuclear medicine, nurses, pharmacists, and advanced practice providers involved in the management of patients with prostate cancer.

Statement of Need/Program Overview
Prostate cancer is the second-leading cause of death in men in the United States. However, new evidence-based treatment strategies for metastatic and nonmetastatic disease, novel targeted therapies, and predictive and prognostic biomarkers are allowing clinicians to treat patients who were previously considered untreatable. In order to take full advantage of these improvements in the care of patients with prostate cancer, join moderator Neal Shore, MD, FACS; the Large Urology Group Practice Association; and your fellow urology/oncology professionals for the Second Annual Virtual Summit on Optimizing Uro-Oncology Care for Patients with Metastatic and Nonmetastatic Prostate Cancer.

Providing real-time interactions and convenience to busy clinicians, the 4-part online summit includes a combination of live and on-demand sessions designed to explore the use of biomarker testing to assess disease risk, new and emerging therapeutic options, treatment-related adverse events, and strategies for selecting the most appropriate treatment for each patient.

Session 1 (on-demand): “Utilizing Biomarkers to Navigate Treatment Decisions for Prostate Cancer Patients,” will examine the role of biomarkers in predicting patients’ risk for prostate cancer and prognosis to determine the optimal treatment choice.

Session 2 (live and on-demand): “Integrating New Therapies in the Management of Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC),” will explore the diagnosis of nmCRPC, updates to the evidence-based guidelines for its treatment, and the latest clinical data on antiandrogen agents.

Session 3 (live and on-demand): “Optimizing Treatment for Patients with metastatic Castration-Resistant Prostate Cancer (mCRPC),” will review strategies for risk stratification of patients, current and emerging therapies, and the selection, initiation, monitoring, and sequencing of treatment for mCRPC.

Session 4 (on-demand): “PARP Inhibition: A New Paradigm in Prostate Cancer Care,” will take a closer look at the utility of PARP inhibitors in the treatment of prostate cancer and discuss the selection of patients who are most likely to benefit from this treatment option.

Educational Objectives
After completing this activity, the participant should be better able to:

Review the rationale behind biomarker testing in prostate cancer to assess patients’ risk and prognosis and determine treatment
Discuss how molecular testing in patients with prostate cancer can guide treatment selection
Review the recent recommendations by NCCN, AUA, and ASCO regarding molecular testing in patients with prostate cancer
Implement physician-patient communication strategies to inform and counsel patients and prostate cancer about molecular testing